ClinicalTrials.gov
ClinicalTrials.gov Menu

Reduction of the Dietary Glycemic Index (GI) by L-Arabinose and Indigestible Dextrin

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01039662
Recruitment Status : Completed
First Posted : December 25, 2009
Last Update Posted : June 23, 2011
Sponsor:
Collaborator:
Unitika Ltd.
Information provided by:
Hiroshima University

Brief Summary:
This study aims to investigate the effect of supplement containing L-arabinose and indigestible dextrin on dietary glycemic index.

Condition or disease Intervention/treatment Phase
Healthy Dietary Supplement: L-arabinose and indigestible dextrin Dietary Supplement: Placebo Not Applicable

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 19 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Effects of the Combination of L-Arabinose and Indigestible Dextrin on Glycemic Index: a Double-Blind, Crossover Trial
Study Start Date : December 2009
Actual Primary Completion Date : December 2010
Actual Study Completion Date : December 2010

Arm Intervention/treatment
Experimental: Oolong tea containing L-arabinose and indigestible dextrin Dietary Supplement: L-arabinose and indigestible dextrin
Placebo Comparator: Oolong tea Dietary Supplement: Placebo



Primary Outcome Measures :
  1. Postprandial glucose level [ Time Frame: 2 hours ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years to 50 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Healthy as based on medical history and physical examination
  • BMI is less or equal to 30 kg/m2
  • Willing not to serve as blood donor during the study
  • Informed consent signed

Exclusion Criteria:

  • Impaired Glucose Tolerance
  • Female subjects who are pregnant or nursing a child
  • Participation in any clinical trial up to 90 days before Day 1 of this study
  • Renal or hepatic dysfunction
  • Heart disease
  • Under medication

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01039662


Locations
Japan
Hiroshima University
Hiroshima, Japan, 734-8551
Sponsors and Collaborators
Hiroshima University
Unitika Ltd.

Responsible Party: Fumiko Higashikawa, Associate professor, Hiroshima University
ClinicalTrials.gov Identifier: NCT01039662     History of Changes
Other Study ID Numbers: eki-199
First Posted: December 25, 2009    Key Record Dates
Last Update Posted: June 23, 2011
Last Verified: June 2011